Compare Sana Biotechnology Inc (SANA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard S&P 500 ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Vanguard S&P 500 ETF trades at $701.8. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VOO | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $714.90 |
52-Week Low | $2.68 | $580.93 |
Enterprise Value | $946.04M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VOO trades at $704.09, down 0.56% on the day, with a neutral technical signal and bullish moving averages. Support is firm near $701, while resistance sits at $707. The ETF remains a core S&P 500 holding, with recent news highlighting its tax efficiency versus gold ETFs and strong inflows amid record ETF launches in 2026.
Long-term outlook remains positive given historical S&P 500 performance, though risks include elevated market valuations and Fed policy uncertainty. The ETF offers broad market exposure, but investors face potential volatility from macroeconomic factors and high concentration in top AI-driven companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
